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Heterogeneity and Plasticity of
Human Breast Cancer Cells in
Response to Molecularly-Targeted
Drugs
Emira Bousoik †‡, Ramina Nabiee ‡, Farideh Amirrad, Ashley Nichols, Rebecca Witt,
Parvin Mahdipoor and Hamidreza Montazeri Aliabadi*
Department of Biomedical and Pharmaceutical Sciences, Chapman University School of Pharmacy, Harry and Diane Rinker
Health Science Campus, Irvine, CA, United States
Non-responsive subpopulation of tumor cells, and acquired resistance in initially
responsive cells are major challenges for cancer therapy with molecularly-targeted
drugs. While point mutations are considered the major contributing factor to acquired
resistance, in this study we explored the role of heterogeneity and plasticity of selected
human breast cancer cell lines (MDA-MB-231, MDA-MB-468, and AU565) in their
initial and adjusted response, respectively, to ruxolitinib, everolimus, and erlotinib. After
determination of lethal concentration for 50% cell death (LC50), cells were exposed
to selected drugs using three different approaches: single exposure to 4 × LC50 and
collection of surviving cells, multiple exposures to 1.5 × LC50 and monitoring the
surviving population, and exposure to gradually increasing concentrations of selected
drugs (range of concentrations equivalent to 10% of LC50 to 1.5× LC50). Surviving cells
were studied for adjustments in expression level of selected proteins using quantitative
PCR and Western Blot. Our data indicated overexpression of a variety of proteins
in resistant populations, which included cell membrane receptors EGFR and HER2,
anti-apoptotic proteins Bcl-2 and BIRC8, and other proteins involved in cell signaling
(e.g., Akt1, MAPK7, and RPS6KA5). Silencing the identified alternative proteins via
siRNA resulted in significant drop in the LC50 of the selected molecularly-targeted drugs
cells resistant to ruxolitinib (via targeting Akt), everolimus (via targeting EGFR, MAPK7,
RPS6KA5, and HER2), and erlotinib (via silencing Bcl2 and BIRC8). Our data indicates
that targeting well-selected alternative proteins could potentially sensitize the resistant
cells to the effect of the molecularly-targeted treatment.
Keywords: breast cancer, resistance, plasticity, heterogeneity, molecularly-targeted drugs
INTRODUCTION
Despite usually promising initial response to newly developed molecularly-targeted drugs (used
individually or in combinations) (1), an initial unresponsive sub-population (force-selected by
the drug) and development of acquired resistance after repeated exposures seem to be inevitable
in cancer cells (2). The innate resistance is usually explained by tumor heterogeneity. Several
hypotheses have been proposed to explain the well-documented intra- and inter-population
heterogeneity of cancer cells. A recent genomic profiling study in 349 patients with colorectal
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tumors suggests that this type of tumors grow predominantly as a
single expansion populated by numerous intermixed sub-clones,
and verifies that most detectable intra-tumor heterogeneity
occurs early during tumor growth and leads to spatial
heterogeneity in each tumor (3). More diverse pattern has been
reported in other types of cancer, including acute lymphoblastic
leukemia (4). While majority of the cells in a given tumor might
respond to the molecularly-targeted drugs, a sub-population
usually survives the treatment, which results in a “Darwinian
clone selection” and tumor relapse (5). On the other hand, tumor
cells could also “acquire” resistance as a result of incomplete
response and multiple exposures to the same anticancer drug.
While multiple mechanisms are involved in this type of resistance
(among which point mutations in the gene expressing the
targeted protein is well-accepted), plasticity of cancer cells could
play a crucial role. While cells rely on an “addiction pathway”
(specific overexpressed and/or overactivated pathway), exposure
to molecularly-targeted drugs could prompt the cells to bypath
the targeted protein by activating alternative or “off-target”
proteins and/or pathways (6).
Multiple pathways play an oncogenic role in different cancer
types, and JAK/STAT, PI3K/Akt, and Ras/Raf/MEK/ERK
pathways are major pathways that have been studied
extensively. JAK/STAT pathway is associated with a variety
of transmembrane receptors. JAK overactivation has been
implicated in tumorigenesis (7), and persistent activation
of STAT3, and to a lesser extent STAT5, has been shown to
increase proliferation, survival, angiogenesis, and metastasis in a
variety of human cancers (8). After transportation into nucleus,
STAT3 acts as a transcription factor, and enhances expression
of antiapoptotic proteins [including Mcl-1 (9), Bcl-2 (10), and
surviving (11)], proteins involved in cell-cycle progression
[including c-Myc and cyclin D1 (12)], and angiogenesis
[including Vascular Endothelial Growth Factor, VEGF (13)].
We have recently reviewed the crucial role of JAK/STAT
pathway in tumorigenic cells (14). PI3K/AKT pathway is one
of the most commonly disrupted pathways in cancer, and
the PI3K-dependent activation of the serine/threonine kinase
AKT is a key factor in many survival mechanisms (15). The
main downstream effector of PI3K/Akt pathway is mechanistic
target of rapamycin (mTOR) (16). Binding of growth factors
to cell surface receptors could also activate Ras/Raf/MEK/ERK
pathway. Mutations in KRAS, BRAF, MEK1, or MEK2 result in
growth factor-independent ERK1 and ERK2 activation, which
enhances cell proliferation and survival (17). While proteins
involved in these mechanisms are traditionally categorized in
specific “pathways,” extensive “crosstalk” among pathways has
been also reported. Activation of mTOR downstream effectors
by p38 MAPK pathway (18), the effect of STAT3 activation on
Ras and PI3K/Akt pathway (19), and JAK2 activation on PI3K
and ERK pathways (20, 21) are examples of these crosstalks,
which could be an important factor in the ability of cancer cells
to “switch” to an alternative pathway for survival.
In this study, we hypothesize that human breast cancer cell
lines could demonstrate a similar heterogeneity and plasticity in
exposure to molecularly-targeted drugs, and we aim to study the
alternative proteins that potentially play a role in inherent and
acquired resistance to these anticancer agents. We selected three
breast cancer cell lines, and three molecularly-targeted drugs:
(a) Ruxolitinib (RUX; pan-JAK inhibitor): Janus kinases (JAKs)
are a family of enzymes involved in JAK/STAT pathway, and
ruxolitinib is a pan inhibitor with more selectivity toward JAK1
and 2 (22). Ruxolitinib has been evaluated in multiple clinical
trials for different types of cancer (23, 24), including breast
cancer (25). It is currently under evaluation in multiple phase I
and II clinical studies, including NCT01594216, NCT02876302,
and NCT02928978; (b) Everolimus (EVE; selective mTORC1
inhibitor): mTOR is one of the downstream effectors of PI3K/Akt
pathways, and everolimus selectively targets the C1 protein
complex (26). It is approved by FDA for breast cancer treatment,
and has been used in clinical settings for different types of cancer
(27, 28); and (c) Erlotinib (ERL; selective ErbB1/EGFR inhibitor):
Small molecules that target Erb family of receptors collectively
(pan-ErbB inhibitors) and selectively, have been studied in
clinical settings. Erlotinib is a selective inhibitor that targets
EGFR specifically, and has been in clinical trials for treatment
of advanced solid malignancies (29). Erlotinib is under extensive
clinical evaluation for breast cancer treatment, including phase
II clinical trials NCT00633750, NCT00054275, NCT00054132,
NCT00834678, NCT00033514, and NCT00733408. EGFR has
been linked to both PIEK/Akt (30) and Ras/Raf/MEK/ERK
pathways (31).
It is important to note that our objective was not to
investigate combination of these selected molecularly-targeted
drugs in breast cancer therapy. Our goal was to identify specific
“alternative” (or “off-target”) proteins with specific role in
resistance against each drug independently. We selected three
small molecule drugs to study resistance mechanisms against
targeting proteins involved in three major signaling pathways:
JAK as the triggering upstream protein in JAK/STAT signaling
axis (with reported cross-talk with other pathways), mTOR as
a downstream and central effector for PI3K/Akt pathway, and
EGFR as a receptor tyrosine kinase (RTK) and upstream factor
for both PI3K/Akt and RAS/Raf/MEK/ERK pathways.
MATERIALS AND METHODS
Materials
Ruxolitinib, everolimus, and erlotinib were purchased from
Selleckchem (Houston, TX). Dulbecco’s modified Eagle’s
medium (DMEM; low glucose with L-glutamine), penicillin
(10,000 U/mL), streptomycin (10 mg/mL), fetal bovine serum
(FBS), and Hank’s Balanced Salt Solution (HBSS) were provided
by Life Technologies (Grand Island, NY). PCR master mixes
(iScriptTM Reverse transcription Supermix and iTaq Universal
SYBR Green Supermix), and all Western Blot requirements
(including Trans-blot R© TurboTM Cassettes, Trans-Blot R©
TurboTM Mini PVDF Transfer Packs, ClarityTM Western ECL
Substrate, and 10% Mini-PROTEAN R© TGX Stain-FreeTM
Protein Gels) were were purchased from Bio-Rad (Hercules,
CA). Cell Counting Kit-8 (CCK-8) assay was supplied by
Biotool (Houston, TX). TRIzol reagent was purchased from
Sigma (St. Louis, MO). The PierceTM Bovine Serum Albumin
Standard Ampules were obtained from ThermoFisher Scientific
Frontiers in Oncology | www.frontiersin.org 2 October 2019 | Volume 9 | Article 1070
Bousoik et al. Response to Drugs in Breast Cancer
(Waltham, MA). Monoclonal antibodies against AKT1 (2H10
Mouse mAb; Cat# 2967, RRID: AB_331160), MAPK7 (Erk5
(D3I5V) Rabbit mAb; Cat# 12950, RRID: AB_2798068), and
β-actin (8H10D10 Mouse mAb; Cat# 3700, RRID: AB_2242334),
and anti-rabbit polyclonal secondary antibody HRP-linked
(Cat# 7074, RRID: AB_2099233) were provided by Cell
signaling Inc. (Danvers, MA). Monoclonal antibodies for
JAK3 (clone 452506; Cat# MAB4699, RRID: AB_2128788),
RPS6KA5 Human MSK1 MAb (clone 252608; Cat# MAB2518,
RRID: AB_2181800), and Bcl-2 (Human/Mouse/Rat Bcl-2
MAb Clone 625509; Cat# MAB8272, RRID: AB_10890789),
fluorescent-labeled monoclonal antibodies for HER2 (Human
ErbB2/Her2 (Trastuzumab) Alexa Fluor 488 MAb Cl Hu5;
Cat# FAB9589G, RRID: AB_2800468), and EGFR (Human EGF
R/ErbB1 Fluorescein-conjugated Antibody; Cat# FAB10951F,
RRID: AB_1096584), and anti-mouse polyclonal secondary
antibody (Goat Anti-Mouse IgG HRP-linked; Cat# HAF007,
RRID: AB_357234) were purchased from R&D Systems
(Minneapolis, MN). All other materials were obtained from
VWR (Radnor, PA). All the primers were designed and ordered
from Integrated DNA Technologies (IDT; Coralville, IA).
Supplementary Table 1 summarizes the sequence of the primers
included in the microarrays used in this study. All primers
were validated by gel electrophoresis (to ensure exclusive
amplification of the target cDNA) and real-time PCR using
differtent cDNA concentrationsm as described before (32). All
the siRNAs used for the study were purchased from Qiagen
(Valencia, CA), and the relevant information is summarized in
Supplementary Table 2.
Cell Lines
Three different breast cancer cell lines were included in this study:
- MDA-MB-231 wild-type (triple negative, but expected to
express EGFR; ATCC R© HTB-26
TM
, RRID: CVCL_0062);
- MDA-MB-468 (triple negative, but over-expresses EGFR;
ATCC R© HTB-132
TM
, RRID: CVCL_0419); and
- AU565 (over-expresses HER2, and expected to express EGFR;
ATCC R© CRL-2351
TM
, RRID: CVCL_1074) (33).
The selected cell lines therefore represent a variety of receptor
expression, and as a result, a range of active signaling pathways.
More detailed information about the selected cell lines are
summarized in Supplementary Table 3. All cell lines were
incubated for the duration of experiments in 37◦C and 5%
CO2 level. Dulbecco’s Low Glucose Modified Eagles Medium
(DMEM), containing L-Glutamine and Sodium Pyruvate and
glucose was used for MDA-MB-231 and MDA-MB-468 cells.
RPMI 1640 medium was used for AU565 cells. Both mediums
were supplemented with 10% (v/v) fetal bovine serum, 100 U/mL
penicillin and 100 µg/ml streptomycin.
Cell Viability Assay
A Cell Counting 8 (CCK8) KIT (Biotool; Houston, TX; also
known as WST-8) was used to evaluate the Lethal concentration
50% (LC50) of molecularly-targeted drugs. After the treatment
period, 10µL of CCK8 reagent was added to each well, and plates
were incubated at 37◦C, 5% CO2 for 2 h. Absorbance of each well
was measured at 450 nm using microplate reader (SpectraMAX
FIGURE 1 | LC50 of selected molecularly-targeted drugs in naïve cells: The selected breast cancer cell lines (MDA-MB-231, MDA-MB-468, and AU565 were
exposed (in triplicates) to a wide range of concentrations of ruxolitinib (RUX), everolimus (EVE), and erlotinib (ERL) and the lethal concentration for 50% cell death
(LC50) was calculated based on a sigmoidal effect (% cell death) model (summarized in the table).
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M5 microplate reader). The results were normalized to cells
treated with normal saline (considered as 100%) after subtracting
the signal from blank wells (medium without cells in the plate
with CCK-8 solution added). All experiments were performed
in triplicates.
LC50 Determination
Cells were seeded in 96-well plates (∼105 cells per well) and
were incubated at 37◦C, 5% CO2 for 24 h. After the incubation
period, cells were exposed to a range of drug concentrations
in triplicates, and were incubated in the same conditions. After
72 h exposure, CCK assay was performed. We estimated LC50
values using sigmoidal effect (% cell death) model according to
the following equation:
% Cell Death =
%Maximum Cell Death × Cγ
LC50γ + Cγ
where C is the concentration of drug, LC50 is the concentration
that produces half of the maximum cell death, and γ is the hill
coefficient (steepness factor). The experimental values of % cell
death and concentration were fitted to the above equation using
non-linear regression analysis and the values of % maximum cell
death, LC50, and γ were estimated. The values for Maximum cell
death, γ, and LC50 are summarized in Supplementary Table 4.
Inherent and Acquired Resistance
Three approaches were used to either collect the inherently non-
responsive cells or to induce resistance in naïve cells: (i) Single
shock method: Cells were exposed to a high concentration of
one of the selected molecularly-targeted drugs, equivalent to 4
× LC50 estimated for each cell line. After 24 h, the medium
containing the drug was replaced with fresh, drug-free medium.
After 72 h of the initial exposure, surviving cells were collected,
and transferred to a cell culture flask, with medium containing
the respective drug equivalent to 50% of LC50 as themaintenance
concentration. The inherent resistance was confirmed by LC50
determination in surviving cells. The total RNA was extracted
from a sample subset of the surviving population; (ii) “Multiple
Exposures”: Cells were exposed to concentrations equivalent to
1.5× LC50 calculated for the drug in each cell line. Exposure was
repeated until a ∼3-fold increase in LC50 value was observed.
After each exposure surviving cells were collected and the LC50
of the drug in the surviving population was determined. The total
RNA was extracted for the resistant cells, and cells were cultured
in medium containing the same maintenance concentration; and
(iii) “Gradual Method”: Exposures started with concentrations
equivalent to 10% of the LC50 calculated for the drug in each
cell line. Each cell population was exposed to each concentration
for three times, before the exposure concentration increased. The
drug concentration was increased step-wise to concentrations
equivalent to 20, 50, 100, and 150% (1.5 ×) LC50. Resistant
FIGURE 2 | LC50 of selected molecularly-targeted drugs surviving 4 × LC50 concentrations of the respective drug: All three selected cell lines were exposed to
ruxolitinib, everolimus, and erlotinib at concentrations equivalent to 4 × LC50 of the drug in each cell line. Surviving cells were collected and maintained in media
containing the respective drug. The LC50 of surviving cells was calculated similarly to naïve cells, and the values are summarized in the table. We were unable to
collect survivors after exposure of MDA-MB-468 cells to erlotinib and after exposure of AU565 cells to either of the selected drugs at these concentrations.
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cells were maintained in medium containing the maintenance
concentration. LC50 was periodically determined for all resistant
cell populations to ensure continuance of the elevated LC50.
Real-Time Polymerase Chain Reaction
(RT-PCR)
RNA was extracted from cells using TRIzol reagent following
the manufacturer’s instructions. Briefly, one mL of TRIzol
reagent was added for each 1 × 106 cells. The cell lysates
were incubated at room temperature for 5min, after which
chloroform (at 1:5 v/v chloroform:TRIzol ratio) was added to
the lysates. The contents of tubes were mixed and incubated
for 2–3min at room temperature, and then the aqueous phase
was collected. Isopropanol was added to precipitate and pellet
RNA using centrifuge (12,000 g for 10min in 4◦C). The pellet
was washed with 75% ethanol, and extracted RNA was dissolved
in RNase-free water. The total extracted RNA in each sample
was determined by BioSpec-Nano (Shimadzu, Columbia, MD).
For cDNA synthesis 0.5–1 µg RNA was reverse transcribed
using iScriptTM reverse transcription Supermix and the C1000
Touch R© thermocycler (Bio-Rad, Hercules, CA), following the
manufacturer’s guidelines. A CFX96TM optical module (Bio-
Rad, Hercules, CA) was used for RT-PCR analysis, while human
β-actin and hypoxanthine phosphoribosyltransferase 1 (HPRT1)
were used as the endogenous gene to normalize the mRNA
level of targeted proteins. RT-qPCR was conducted using iTaq
universal SYBR green Supermix kit. Cycling conditions were as
follows; 95◦C for 2min, followed by 40 cycles of denaturation
95◦C for 5 s and annealing temperature 55◦C for 30 s, and a
final extension step at 65◦C for 5 s. Analysis was performed by
calculating11CT (using the average1CT calculated for each of
the endogenous genes) and relative quantity (RQ). The mRNA
levels were determined as a microarray format including 46
targeted proteins. The sequence of the primers used in this study
are summarized in Supplementary Table 1.
Western Blot
Protein expression of selected targets was analyzed by Western
blot. Cell protein lysates were prepared according to standard
protocol using RIPA buffer. Briefly, treated and transfected cells
were collected by trypsinization, and the cell suspension was
centrifuged at 800 RPM for 5min. Then the supernatant was
discarded, and the cell pellet was washed three times with ice
cold PBS and then 100 µL of RIPA buffer was added to 25
µL of cell pellet and pipetted up and down. The cell lysates
were then incubated on ice for 1 h, during which the tubes were
sonicated (for 3min) on ice and mixed every 10min. The tubes
centrifuged at 12,000 g for 15min at 4◦C. The supernatant was
transferred to pre-cooled tubes, and total protein concentration
was determined using BSA assay according to standard protocol.
Briefly, 200 µL of work reagent (50:1 A:B) was added to 25 µL
of standard and unknown sample in triplicate into a microplate
FIGURE 3 | LC50 of ruxolitinib in cells surviving multiple exposure to 1.5 × LC50 concentrations of ruxolitinib. Cells were exposed to the specified concentration for
total of five exposures. The LC50 of drug in corresponding surviving cell populations was calculated similarly to naïve cells, and the values are summarized in the
corresponding table. We were unable to collect survivors after the first exposure of AU565 cells to ruxolitinib at these concentrations.
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well, plated was mixed on plate shaker for 30 s then it was
incubated at 37◦C in 5% CO2 for 30min. Then the absorbance
was measured at 562 nm using microplate reader (SpectraMAX
M5 microplate reader). Protein (25 µg) was loaded per well
in a 10% Mini-PROTEAN R© TGX Stain-FreeTM Protein gel
using electrophoresis buffer (0.192M glycine, 25mM Tris, 0.1%
SDS), and the electrophoresis was run for 30min with 200V.
After electrophoresis, the gel was transferred onto a Trans-
Blot R© TurboTM Mini PVDF membrane (Catalog No. 1704156).
Membranes were blocked in BSA 5% for 3 h, and then incubated
overnight (at 4◦C) with the primary anti-body (1:1,000 in TBS-
T). Then, the membrane was washed with TBS-T six times
(5min for each time). Then the membrane was incubated with
secondary HRP-linked antibody (1:1,000 in TBS-T) for 1 h. Then
the washing step was repeated. Detection was done by ECLDetect
Kit using ChemiDoc imager (Bio-Rad).
Flow Cytometry
The expression level of EGFR and HER2 was evaluated by
exposing the cells to FAM-labeled antibody for the receptors
of interest, and the fluorescence signal was measured by flow
cytometry (BD-FACSVerse; BD Biosciences; San Jose, CA), using
FITC channel. Cells were trypsinized and collected, washed with
HBSS, and then re-suspend in 10ml of staining Buffer. 200
µL of the suspension was transferred to small tubes (triplicate)
and 5 µl of antibody was added to each. The Tubes were
incubated in 4◦C for 30min. After incubation, tubes were
centrifuged and the supernatant was discarded. Cells were
washed with HBSS to remove unbound antibody and fixed
by addition of 400 µL of 3.7% formaldehyde to each tube.
The percentage of cells with fluorescence signal and the mean
fluorescence of the cell population were calculated based on
the calibration of the signal gated with non-treated cells (as the
negative control).
Protein Silencing
For silencing experiments, we included a Control siRNA
(CsiRNA) group, where cells received scrambled siRNA as a
negative control. Cells were seeded into six-well culture plates
with antibiotic-free culturemedium at 50% confluency (∼6× 105
cells). After 24 h of incubation in 37◦C, siRNA transfection was
performed using Lipofectamine R© 2000 reagent. Lipofectamine R©
2000 reagent was diluted with Opti-MEM medium in 1:100
ratio. Opti-MEM medium was also used to dilute 10 nM siRNA
at ratio of 1:50. After 5min, diluted siRNA was mixed with
Lipofectamine R© 2000 reagent in one tube and incubated for
20min at room temperature. Then, 500 µL of the complex
solution was added to each well after removing the growth
medium. Cells were incubated at 37◦C for 6 h, after which, the
medium containing complexes was removed and replaced by
antibiotic-free culture medium for the rest of incubation time (72
h total).
FIGURE 4 | LC50 of everolimus in cells surviving multiple exposure to 1.5 × LC50 concentrations of everolimus. Cells were exposed to the specified concentration of
everolimus for total of five exposures. The LC50 of drug in corresponding surviving cell populations was calculated similarly to naïve cells, and the values are
summarized in the corresponding table. We were unable to collect survivors after the third exposure of MDA-MB-468 cells, and after second exposure of AU565 cells
to everolimus at these concentrations.
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FIGURE 5 | LC50 of erlotinib in cells surviving multiple exposure to 1.5 × LC50 concentrations of erlotinib. Cells were exposed to the specified concentration of
erlotinib for total of five exposures. The LC50 of each drug in corresponding surviving cell populations was calculated similarly to naïve cells, and the values are
summarized in the corresponding table. We were unable to collect survivors after the fifth exposure of AU565 cells to erlotinib at these concentrations.
FIGURE 6 | LC50 of ruxolitinib in MDA-MB-231 and MDA-MB-468 after multiple exposures to gradually increasing concentrations of the drug: All three selected cell
lines were exposed to ruxolitinib at gradually increasing concentrations (starting at 10% of the estimated LC50 value and up to 1.5 × LC50; at least three times for
each concentration). The LC50 in corresponding cell lines was calculated with the similar method as for naïve cells, and the values are summarized in the table. We
were unable to collect AU565 cells after the third exposure to 10% of estimated LC50 value for ruxolitinib.
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FIGURE 7 | LC50 of everolimus after multiple exposures to gradually increasing concentrations of the drug: All three selected cell lines were exposed to everolimus at
gradually increasing concentrations (starting at 10% of the estimated LC50 value and up to 1.5 × LC50; at least three times for each concentration). The LC50 in
corresponding cell lines was calculated with the similar method as for naïve cells, and the values are summarized in the table. We were unable to collect AU565 cells
after the third exposure to 10% of estimated LC50 value for everolimus.
FIGURE 8 | LC50 of erlotinib after multiple exposures to gradually increasing concentrations of the drug: All three selected cell lines were exposed to erlotinib at
gradually increasing concentrations (starting at 10% of the estimated LC50 value and up to 1.5 × LC50; at least three times for each concentration). The LC50 in
corresponding cell lines was calculated with the similar method as for naïve cells, and the values are summarized in the table. We were unable to collect AU565 cells
after the third exposure to 50% of estimated LC50 value for erlotinib.
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RESULTS
Isolation of Innately Resistant Cells and
Resistance Induction
We determined the LC50 of selected drugs in each cell line
(Figure 1) as a basis for calculation of concentrations used in
future experiments. Among the selected drugs, everolimus and
ruxolitinib showed the highest and lowest potency, respectively.
Also, MDA-MB-231 cells showed the lowest sensitivity to the
selected molecules with highest LC50 observed for all selected
molecules. The lowest LC50 was calculated for everolimus in
AU565 cells.
The non-responsive cells were isolated by exposing naïve cells
to a concentration 4-fold the calculated LC50 in each cell line.
This method was unsuccessful in AU565 cells, where we were
not able to collect any survivors. We faced a similar challenge
with MDA-MB-468 cells exposed to 4× LC50 of erlotinib, where
no cells were collected after exposure. The LC50 of the selected
drug in the collected cells was compared to the naïve population
(Figure 2), where at least a 2-fold increase in LC50 was observed.
MDA-MB-231 Cells surviving the exposure to 4 × LC50 of
everolimus showed the lowest difference in LC50 compared to
naïve cells (∼2.8-fold), where the MDA-MB-468 cells collected
after same treatment with everolimus demonstrated the highest
difference (∼8.6-folds).
For ruxolitinib, Multiple Exposures gradually increased the
LC50 in MDA-MB-231 and MDA-MB-468 cells (to 3.9-folds and
5.3-folds after fifth exposure, respectively; Figure 3). Performing
the same exposure method for everolimus was only successful in
MDA-MB-231 cells (Figure 4), where a similar gradual increase
was observed after 3rd exposure, and a 4.8-fold increase in
LC50 was calculated after the 5th exposure. MDA-MB-468 cells
only tolerated two exposures, which did not increase the LC50
significantly. For AU565 cells, we were only able to collect
and grow cells after one exposure, with minimal change in
LC50. Increase in LC50 was achieved for erlotinib in MDA-
MB-231 and MDA-MB-468 cells using Multiple Exposures
(Figure 5). Similar to our observation in everolimus experiments,
exposures 1 and 2 did not affect the LC50 significantly in
MDA-MB-231 cells; however, a significant increase in LC50
was observed in MDA-MB-231 and MDA-MB-468 cells after
the 5th exposure (3.3- and 6.6-fold increase, respectively).
AU565 cells survived four exposures without an increase
in LC50.
Resistance to ruxolitinib was induced in MDA-MB-231 and
MDA-MB-468 cells via Gradual Method, which demonstrated
FIGURE 9 | Analysis of mRNA expression level of selected proteins in resistant vs. naïve cell populations: Proteins were selected in different categories (involved in
JAK/STAT, PI3K/Akt, Ras/Raf pathways, as well as pro-apoptosis, and anti-apoptosis proteins, and proteins involved in cell cycle regulation and miscellaneous
proteins) and were included in a microarray along with β-actin and HPRT1 as endogenous proteins. The results for resistant cells to ruxolitinib were normalized based
on relative quantities observed in corresponding naïve cell populations, and are presented as heatmaps and volcano graphs. The criteria for significant overexpression
were set at 5-fold increase in mRNA level and p < 0.05. See Supplementary Figure 1 for corresponding scatterplots.
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a gradual increase in LC50 values after each increase in
concentration, and a 2.9- and 4.7-fold increase in LC50
value was calculated after exposure to highest concentration,
respectively (Figure 6). AU565 cells never truly recovered
after exposures to 10% of LC50 values. A similar trend
was observed in response to gradual increase in everolimus
concentrations, where AU565 cells were removed from the
studies, and a 3.1- and 5.7-fold increase in LC50 was observed for
MDA-MB-231 and MDA-MB-468 cells, respectively (Figure 7).
Gradual Method for erlotinib in MDA-MB-231 and MDA-
MB-468 cells resulted in 5.7- and 6.8-fold increase in LC50
compared to naïve populations, respectively. AU565 survived
gradual increase in erlotinib concentrations equivalent to up
to 50% of LC50 without a significant increase in LC50
values. However, we were not able to recover the cells
after repeated exposure to concentrations equivalent to LC50
value (Figure 8).
Profiling Protein Expression
The mRNA levels are presented as heat maps, and scatter
and volcano plots, where 5-fold increase or decrease in
mRNA levels (as well as p-value of 0.05 for volcano plots)
were selected as the cut-off to identify the most significant
discrepancies. Our observations after exposure of MDA-MB-231
and MDA-MB-468 to ruxolitinib (as summarized in the heat
map presented in Figure 9) indicated different adjustments
in mRNA level of many selected proteins (for instance, the
opposite changes in expression level of Myc in different study
groups, or significant overexpression of Akt1 in MDA-MB-
468 cells exposed to ruxolitinib via Gradual Method that
was not seen in any other study groups). This emphasizes
the different reactions to ruxolitinib exposure depending on
the cell type and exposure method. However, consistencies
were also detected, which could be summarized as: (i)
consistent KRas overexpression across the map; (ii) consistent
downregulation of cyclin D1; and CDK6 across the map; (iii)
significant overexpression of JAK3 and SOCS3 in both cell
lines surviving 4 × LC50 concentration; (iv) overexpression
of all proteins categorized as “anti-apoptotic” (except BCL-XL)
or under Ras/Raf pathway in MDA-MB-468 cells for Gradual
Method; and (v) downregulation of all proteins categorized
as “pro-apoptosis” in MDA-MB-231 cells repeatedly exposed
to ruxolitinib (gradually increasing or equal concentrations).
The volcano plots present the most significant up-and down-
regulated proteins in study groups. JAK3 and SOCS3 were
identified as proteins overexpressed in cells surviving 4 × LC50
of ruxolitinib in both cell lines, and while Multiple Exposure
method did not identify any significant overexpression, Gradual
FIGURE 10 | Analysis of mRNA expression level of selected proteins in resistant vs. naïve cell populations: Proteins were selected in different categories (involved in
JAK/STAT, PI3K/Akt, Ras/Raf pathways, as well as pro-apoptosis, and anti-apoptosis proteins, and proteins involved in cell cycle regulation and miscellaneous
proteins) and were included in a microarray along with β-actin and HPRT1 as endogenous proteins. The results for resistant cells to everolimus were normalized based
on relative quantities observed in corresponding naïve cell populations, and are presented as heatmaps and volcano graphs. The criteria for significant overexpression
were set at 5-fold increase in mRNA level and p < 0.05. See Supplementary Figure 1 for corresponding scatterplots.
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FIGURE 11 | Analysis of mRNA expression level of selected proteins in resistant vs. naïve cell populations: Proteins were selected in different categories (involved in
JAK/STAT, PI3K/Akt, Ras/Raf pathways, as well as pro-apoptosis, and anti-apoptosis proteins, and proteins involved in cell cycle regulation and miscellaneous
proteins) and were included in a microarray along with β-actin and HPRT1 as endogenous proteins. The results for resistant cells to erlotinib were normalized based
on relative quantities observed in corresponding naïve cell populations, and are presented as heatmaps and volcano graphs. The criteria for significant overexpression
were set at 5-fold increase in mRNA level and p < 0.05. See Supplementary Figure 1 for corresponding scatterplots.
Method resulted in significant overexpression of Akt1 mRNA in
MDA-MB-468 cells.
The pattern of response to everolimus was different, and a
higher number of discrepancies in mRNA levels was observed in
study groups overall. Notable discrepancies included: (i) lower
mRNA level for mTOR and PTEN, as well as pro-apoptotic
proteins BAX, P53, and BAD in all study groups (except for
BAD in MDA-MB-468 cells exposed to 4 × LC50 concentration
of everolimus); (ii) overexpression of eIF4 (except for Multiple
Exposures inMDA-MB-231 cells), S6K1 (except in cells surviving
4 × LC50 in MDA-MB-231 cells), MAPK3, MAPK5 (except in
Gradual Method in MDA-MB-468 cells), RPS6KA5 (except for
Multiple Exposures in MDA-MB-231 cells), and Mcl-1 in all
study groups; (iii) opposite results for mRNA levels of mLST8,
ATG13, TSC1, and TSC2 (overexpression or no change in cells
surviving 4 × LC50 concentrations, and downregulation after
Multiple Exposures); (iv) multiple significant discrepancies in
survivors of 4 × LC50 in both cell lines (more than any other
study group included in this study), including overexpression
of EGFR in both cell lines, and downregulation of P53 and
PTEN in MDA-MB-231 and MDA-MB-468 cells, respectively;
(v) significant overexpression of MAPK7 and downregulation
of mTOR in MDA-MB-231 cells after Multiple Exposures; and
(vi) significant downregulation of mTOR in both cell lines, and
overexpression of RPS6KA5 and HER2 in MDA-MB-231 and
MDA-MB-468 cells, respectively (Figure 10).
The overall number of expression discrepancies in cells
exposed to erlotinib was less than our observations in cells
exposed to everolimus. Significant overexpression was observed
for JAK3 (Multiple Exposures in MDA-MB-231 cells), Bcl2, and
BIRC8 (Gradual method in MDA-MB-231 and MDA-MB-468
cells, respectively; Figure 11). Overexpression of selected anti-
apoptotic proteins in most of the study groups was another
notable discrepancy.
Sensitizing Resistant Cells by Targeting
“Alterative” Protein
Silencing of the identified proteins in resistant cells was
performed via siRNA delivery to confirm the role of the non-
targeted proteins in resistance against selected small molecules.
JAK3 was identified as an overexpressed protein in three
resistant cell populations (MDA-MB-231 and MDA-MB-468
cells surviving 4 × LC50 of ruxolitinib, and MDA-MB-231
cells surviving Multiple Exposures to erlotinib). The silencing
efficiency was confirmed using Western Blot; however, it did
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FIGURE 12 | Sensitizing the resistant cells to the effect of ruxolitinib by silencing identified alternative proteins: Lipofectamine® 2000 was used for siRNA silencing of
JAK3 in MDA-MB-231 cells surviving 4 × LC50 concentrations ruxolitinib (A), and Akt1 in MDA-MB-468 cells with acquired resistance to ruxolitinib (B). The LC50
values were calculated in naïve cells, naïve cells exposed to siRNA targeting the alternative protein, resistant cells, resistant cells exposed to scrambled siRNA, and
resistant cells exposed to siRNA targeting the alternative protein. The LC50 values were calculated via the same sigmoidal effect (% cell death) model and are
summarized in corresponding tables. The silencing of targeted alternative protein was confirmed via Western Blot.
not change the LC50 of resistant cells to the selected small
molecule significantly, as compared to resistant cells exposed to
scrambled (control) siRNA (CsiRNA) in any of the three cell
populations (JAK3 silencing in MDA-MB-231 cells surviving 4
× LC50 of ruxolitinib is presented in Figure 12A). A similar
observation was made for silencing SOCS3 in both cell lines
after surviving 4 × CL50 of ruxolitinib (data not shown).
Unlike JAK3 and SOCS3, silencing Akt1 (confirmed by Western
Blot) in MDA-MB-468 cells exposed to gradually increasing
concentrations of ruxolitinib reduced the LC50 for ruxolitinib to
half (38.5 vs. 76.1µM) for cells exposed to CsiRNA) in resistant
cells (Figure 12B). Silencing Akt1 in naïve cell population had
a minimal effect on ruxolitinib LC50 (13.3 vs. 17.6µM for
naïve cells).
In cells surviving 4 × LC50 of everolimus EGFR showed the
most significant overexpression (in terms of fold increase) in
both cell lines. EGFR silencing was confirmed by flowcytometry
experiments and had minimal effect on everolimus LC50
in MDA-MB-468 naïve cells (5.4 vs. 7.3µM). However,
targeting EGFR via siRNA reduced everolimus LC50 in
cells surviving 4 × LC50 by 2.6-folds (21.1 vs. 54.9µM for
resistant cells exposed to CsiRNA; Figure 13A). Silencing
EGFR in MDA-MB-231 cells surviving 4 × LC50 created
a similar impact on everolimus LC50 (2.2-folds reduction
in LC50; data not shown). Similarly, silencing MAPK7
in naïve MDA-MB-231 cell populations had a minimal
effect on LC50 (9.8 vs. 12.6µM), and similar interference
reduced everolimus LC50 by ∼2-folds in resistant cells
(32.5 vs. 63.1µM in resistant cells exposed to CsiRNA;
Figure 13B). Silencing RPS6KA5, while not impactful on
everolimus LC50 in naïve MDA-MB-231 cells (11.4 vs.
12.6µM), reduced everolimus LC50 by 1.8-folds (19.1 vs.
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FIGURE 13 | Sensitizing the resistant cells to the effect of everolimus by silencing identified alternative proteins: Lipofectamine® 2000 was used for siRNA silencing of
EGFR in MDA-MB-468 cells surviving 4 × LC50 concentrations of everolimus (A), and MAPK7 in MDA-MB-231 cells surviving multiple exposures to 1.5 × LC50
concentrations of everolimus (B). The LC50 values were calculated in naïve cells, naïve cells exposed to siRNA targeting the alternative protein, resistant cells,
resistant cells exposed to scrambled siRNA, and resistant cells exposed to siRNA targeting the alternative protein. The LC50 values were calculated via the same
sigmoidal effect (% cell death) model and are summarized in corresponding tables. The silencing of targeted alternative protein was confirmed via Western Blot for
MAPK7 and flowcytometry for EGFR.
35.0µM for resistant cells exposed to CsiRNA) in resistant
cell population (Figure 14A). And finally, targeting HER2
(confirmed via flowcytometry) in MDA-MB-468 cells with
induced resistance to everolimus reduced everolimus LC50
by 2.8-folds (13.8 vs. 39.0µM for exposure to CsiRNA), with
minimal effect on everolimus LC50 in naïve population (6.0 vs.
7.3µM; Figure 14B).
In addition to silencing JAK3 in MDA-MB-231 cells surviving
Multiple Exposures to erlotinib, Bcl2 and BIRC8 were also
selected for siRNA silencing in cells with induced resistance
to erlotinib. Bcl2 silencing in naïve MDA-MB-231 cells did
reduce erlotinib LC50 to ∼72% of the original observed
value (13.4 vs. 18.7µM). It also reduced everolimus LC50
in MDA-MB-231 cells with induced resistance to erlotinib
by more than 3.2-folds (30.0 vs. 97.21µM for resistant
cells exposed to CsiRNA; Figure 15A). BIRC silencing was
confirmed via qPCR, since monoclonal antibody for Western
Blotting was not available by either of selected vendors.
Silencing BIRC8 showed more than 3-folds decrease in erlotinib
LC50 in resistant cells (18.9 vs. 57.7 µL for exposure
to CsiRNA), with minimal effect in naïve cells (7.9 vs.
8.9µM; Figure 15B).
DISCUSSION
Three targets were selected to study the role of alternative
proteins in resistance against molecularly targeted drugs
targeting one or more of the major signaling pathways. JAK2
has a crucial role in cancer cell proliferation and survival, not
only via activation of STATs and downstream proteins, but
also through inter-pathway cross-talk to activate PI3K/AKT
and MEK/ERK signaling (20, 21). EGFR is an important RTK,
which is also known to trigger multiple signaling cascades (AKT,
RAS/RAF, and STATs), even independent from the growth factor
ligands (34). And finally, mTOR is a downstream effector of the
PI3K/AKT pathway with a central role in multiple intracellular
mechanisms (including autophagy, microtubule organization,
and protein and lipid synthesis) (35). According to a recent
study of breast cancer cell lines, while JAK/STAT pathway is not
over-activated in selected cell lines for this study (compared to
non-cancerous breast cancer cell lines), the activation level in
AU565 cells is higher than MDA-MB-231 and MDA-MB-468 cell
lines. On the other hand, PI3K/Akt pathway is over-activated
in all three cell lines, with AU565 showing the highest level of
overactivation (36).
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FIGURE 14 | Sensitizing the cells with acquired resistance to the effect of everolimus by silencing identified alternative proteins: Lipofectamine® 2000 was used for
siRNA silencing of RPS6KA5 in MDA-MB-231 cells with acquired resistance to everolimus (A), and HER2 in MDA-MB-468 cells with acquired resistance to everolimus
(B). The LC50 values were calculated in naïve cells, naïve cells exposed to siRNA targeting the alternative protein, resistant cells, resistant cells exposed to scrambled
siRNA, and resistant cells exposed to siRNA targeting the alternative protein. The LC50 values were calculated via the same sigmoidal effect (% cell death) model and
are summarized in corresponding tables. The silencing of targeted alternative protein was confirmed via Western Blot for RPS6KA5 and flowcytometry for HER2.
mTOR is targeted by everolimus (along other small molecules;
approved by FDA in breast cancer treatment) and is also one of
the few intracellular proteins targeted by FDA-approved small
molecule drugs (along with CDK4/CDK6 and PARP enzyme).
Although ruxolitinib and erlotinib are not currently approved by
FDA for breast cancer treatment, they are under investigation
in multiple clinical trials for this purpose, and were included
in the study since no drug targeting JAK2 or EGFR specifically
(lapatinib inhibits both EGFR and HER2) is included in the
FDA-approved list for breast cancer treatment at this time.
A wide range of values are usually reported for the potency
of molecularly-targeted drugs, which includes cell-free assays,
toxicity assays, and function assays. For instance, while 320 nM
ruxolitinib was reported to eliminate the enhancing effect of G-
CSF in HT93A leukemia cells (37), a ruxolitinib concentration
of at least 50µM was required to induce a significant drop in
cell proliferation in hepatocellular carcinoma cell lines HuH7,
SNU182, and SNU423 (38). In this study, the LC50 values in
naïve cells were in micromolar range, with the least sensitivity
to all three selected drugs observed in MDA-MB-231 cells. This
was especially significant in LC50 values observed for erlotinib,
where the LC50 value in MDA-MB-231 cells was more than 2-
folds higher than the value calculated for MDA-MB-468 cells
(Figure 1). This could be explained by the significantly higher
expression level of EGFR in MDA-MB-468 cells compared to
MDA-MB-231 cells (33).
The three selected approaches to creating resistant cell
populations represent different scenarios: Using an “extremely
high” concentration of the drugs (4-folds the estimated LC50
value) almost exclusively collects the cells that do not respond
to the selected drugs in clinically relevant concentrations. This
is confirmed by the significantly higher LC50 values in the cells
that survived this concentration (Figure 2). Repeated exposures
to 1.5 × LC50 concentrations, on the other hand, will most
likely isolate a combination of cells with inherent and induced
resistance. While a significant proportion of the sensitive cells
are eliminated after each exposure, the concentration is not
high enough to eliminate all the sensitive cells to the selected
drug. Also, the repeated treatments provided the opportunity
for the sensitive cells that were exposed to sub-effective
concentrations to adapt and activate the alternative signaling.
The gradual increase in estimated LC50 values indicate the
gradual selection/adaptation nature of the process (Figures 3–
5). A similar gradual increase in LC50 values was observed
for the Gradual Method (Figures 6–8). However, this approach
provided a better opportunity for the cells to adapt, by starting
with significantly lower concentrations, since exposure to each
concentration was repeated at least three times. The cells
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FIGURE 15 | Sensitizing the resistant cells to the effect of erlotinib by silencing identified alternative proteins: Lipofectamine® 2000 was used for siRNA silencing of
Bcl-2 in MDA-MB-231 cells with acquired resistance to erlotinib (A), and BIRC8 in MDA-MB-468 cells with acquired resistance to erlotinib (B). The LC50 values were
calculated in naïve cells, naïve cells exposed to siRNA targeting the alternative protein, resistant cells, resistant cells exposed to scrambled siRNA, and resistant cells
exposed to siRNA targeting the alternative protein. The LC50 values were calculated via the same sigmoidal effect (% cell death) model and are summarized in
corresponding tables. The silencing of targeted alternative protein was confirmed via Western Blot for Bcl-2 and qPCR for BIRC8.
collected at the end of this process most probably represent cells
with acquired resistance.
We were not able to collect AU565 resistant cells to none
of the selected drugs. The 4 × LC50 concentration simply
wiped off all the cells and repeated exposures either resulted
in no surviving cells (e.g., after second exposure to everolimus;
Figure 4), or did not significantly changed the LC50 in the
surviving cells (e.g., after four repeated exposures to erlotinib;
Figure 5). The triple-negative breast cancer cells (TNBCs) are
notoriously less responsive to anticancer treatment. However,
AU565 cells were included in this study for comparison to the
two TNBC cell lines. Our results indicate a lower heterogeneity
in the population of AU565 cells and/or a lack of plasticity to
adapt to multiple exposures to selected drugs. Also, the fact that
both major targeted signaling pathways are more active in AU565
cells compared to the selected TNBC cells (36), might play an
important role in a higher sensitivity in this cell line to the
selected small molecule drugs. And finally, different approaches
to collecting inherently resistant cells and/or inducing resistance
could potentially be successful in creating a resistant population
of this cell line.
We analyzed the mRNA level of selected proteins. Selections
were made considering the molecularly-targeted drug to which
the cells were resistant, and were based on literature and our own
previously reported findings. For example, SOC1 and SOC3 were
included in microarrays evaluating cells resistant to ruxolitinib,
due to their inhibitory effect on JAK/STAT pathway (39, 40).
On the other hand, we have previously identified RPS6KA5 and
ACVR1 as kinases that showed promising synergistic effect in
combinatorial silencing with Mcl-1 (32).
KRas was consistently overexpressed (less than the arbitrary
threshold of 5-folds increase) in cells surviving ruxolitinib
exposure, and could be further studies as a potential alternative
signaling avenue to compensate for JAK signaling. An interesting
finding was the overexpression of SOCS1 and SOCS3 in cells
with inherent resistance to ruxolitinib. This indicates that lack
of response to ruxolitinib could be due to non-active JAK/STAT
signaling (as opposed to overwhelming overactive pathway). In
other words, cells do not respond to the molecularly-targeted
drug, since the target is simply not important in the survival
of this specific population of cells. A similar pattern was
observed for JAK3 (Figure 9). Springuel et al. have reported a
“cooperation” between JAK1 and JAK3 mutants, which results
in resistance to JAK1/2 inhibitors in TS1 cells (41). Our results
indicate overactivation of JAK3 in cells inherently resistant to
ruxolitinib, and in fact, SOCS3 and JAK3 were the only proteins
in the microarray that were overexpressed beyond the 5-fold
increase threshold in this population. Interestingly, targeting
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neither of these proteins via siRNA silencing sensitized the cells
to ruxolitinib (Figure 12A). This is certainly expected in the
case of SOCS3, since silencing this inhibitory mechanism of
JAK/STAT axis would only further activate the targeted signaling.
JAK3 is known as a potential target for immunosuppression
and cooperation with JAK1 (42), and our results indicate that
JAK3 overexpression does not play a direct role in resistance
to ruxolitinib. Perhaps more interestingly, JAK3 overexpression
was also observed in cells surviving 4 × LC50 concentration and
Multiple Exposures to Erlotinib. However, silencing JAK3 these
cells did not sensitize them to the effect of Erlotinib either.
Akt1 was selected as the target with highest level of
overexpression in MDA-MB-468 cells with acquired resistance
to ruxolitinib. Unlike our observation with JAK3 and SOCS3,
silencing Akt1 significantly reduced the LC50 in the resistant
cells. Multiple reports indicate the role of JAK2 in activation of
Akt signaling (43, 44). A cross-talk between STAT5 (activated
by JAK2) and Akt1 has also been reported that is essential
for progression of breast cancer (45). Our results indicate a
compensatory role for Akt1 for cell survival after JAK inhibition
via ruxolitinib.
EGFR was overexpressed in both cell lines in cell population
surviving 4 × LC50 of everolimus. EGFR is known to activate
both PI3K/Akt and Ras/Raf/MEK/ERK pathways, and this
overexpression in cells non-responsive to everolimus might
indicate an overactivation of Ras/Raf/MEK/ERK axis as an
alternative signaling to mTOR. This speculation is further
confirmed by the significant overexpression of BRaf, KRas, and
MAPK8 in MDA-MB-231 cells and KRas, MAPK3, and MAPK5
in MDA-MB-468 cells with inherent resistance to everolimus.
Downregulation of mTOR and Akt1 in resistant MDA-MB-231
cells is also another indication of relatively inactivated PI3K/Akt
pathway in favor of Ras/Raf/MEK/ERK pathway in this sub-
population. Silencing EGFR sensitized these cells to everolimus.
After surviving Multiple Exposures to everolimus, MDA-MB-
231 cells overexpressed MAPK7, which is again an indication
of activation of Ras/Raf/ERK/MEK axis. Silencing MAPK7
reduced LC50 to approximately half in resistant cells. Also,
after induction of acquired resistance to everolimus, mTOR was
downregulated in both cell lines, which indicates inactivation of
this signaling pathway in favor of alternative mechanisms. These
cell lines showed different overexpression profiles. RPS6KA5
was overexpressed significantly in MDA-MB-231 cells. We have
previously reported a synergistic effect for this kinase and anti-
apoptotic Mcl-1 (32, 46, 47). HER2 was identified as the most
significant overexpression in MDA-MB-468 cells with acquired
resistance to everolimus. Similar to EGFR, HER2 is known
to activate both PI3K/Akt and Ras/Raf/MEK/ERK pathways,
and overexpression of HER2 seems to work as a compensating
signaling pathway in acquired resistance to everolimus in a
cell line that is not known for HER2 expression. Silencing
RPS6KA5 and HER2 were also effective in sensitizing resistant
cells to everolimus.
Anti-apoptotic proteins played a more important role in
acquired resistance against erlotinib (Bcl2 and BIRC8 in MDA-
MB-231 and MDA-MB-468, respectively). The role of anti-
apoptotic proteins in resistance against molecularly-targeted
drugs has been reported. In 2006, Schulze-Bergkamen et al.
reported sensitizing hepatocellular carcinoma cells by siRNA
silencing of Mcl-1 to several cytotoxic and molecularly-targeted
agents, including AG1478 as an EGFR inhibitor (48). Our
experiments showed a significant reduction in erlotinib LC50
in the selected cell lines after targeting Bcl2 and BIRC8 as well,
which is aligned with other researchers’ observations.
Overall, our data reveals involvement of a variety of
alternative proteins involved in innate and acquired resistance
to molecularly-targeted drugs. It has previously reported that
in cancer cells sensitive to RTK inhibitors, PI3K signaling
is initially lost; however, cells become resistant by finding
other routes to activate PI3K signaling (49). These alternative
signaling pathways are either innately overactivated in lieu of
targeted protein (indicating heterogeneity responsible for innate
non-responsiveness of a subpopulation of the cells), or are
overactivated as an intracellular modification as a reaction to
the molecularly-targeted drug (representing the plasticity of the
cancer cells involved in acquired resistance). Our data also
indicates that targeting well-selected alternative proteins could
potentially sensitize the resistant cells to the effect of the original
molecularly-targeted drug.
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